
Axcelis Technologies has delivered a strong 5 year share price gain, yet the stock now screens as expensive on several valuation checks and carries a low overall value score. For investors, the recent pullback raises the question of whether this is a healthy reset or a sign that earlier enthusiasm pushed the valuation too far. Axcelis Technologies has returned about 127% over 5 years, which points to a stock that has already rewarded patient holders. The company’s ability to convert its...
